Literature DB >> 14581576

A bipartite late-budding domain in human immunodeficiency virus type 1.

Juan Martin-Serrano1, Paul D Bieniasz.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) encodes a PTAP motif within the p6 domain of Gag that recruits Tsg101 and associated factors to facilitate virion budding. In this study, we use trans-complementation assays to demonstrate that the PTAP motif acts synergistically with additional p6 sequences to mediate the formation of infectious extracellular HIV-1 virions. These studies suggest that Tsg101 recruitment is necessary but not sufficient to account for late-budding activity exhibited by HIV-1 p6.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14581576      PMCID： PMC254264          DOI： 10.1128/jvi.77.22.12373-12377.2003

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  29 in total

1.  HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress.

Authors:  J Martin-Serrano; T Zang; P D Bieniasz
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

2.  Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I.

Authors:  D J Katzmann; M Babst; S D Emr
Journal:  Cell       Date:  2001-07-27       Impact factor: 41.582

3.  Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding.

Authors:  J E Garrus; U K von Schwedler; O W Pornillos; S G Morham; K H Zavitz; H E Wang; D A Wettstein; K M Stray; M Côté; R L Rich; D G Myszka; W I Sundquist
Journal:  Cell       Date:  2001-10-05       Impact factor: 41.582

4.  Mutations in the PPPY motif of vesicular stomatitis virus matrix protein reduce virus budding by inhibiting a late step in virion release.

Authors:  H R Jayakar; K G Murti; M A Whitt
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding.

Authors:  R N Harty; M E Brown; G Wang; J Huibregtse; F P Hayes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

6.  Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function.

Authors:  Dimiter G Demirov; Akira Ono; Jan M Orenstein; Eric O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

7.  The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner.

Authors:  Dimiter G Demirov; Jan M Orenstein; Eric O Freed
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

8.  Ubiquitination of HIV-1 and MuLV Gag.

Authors:  D E Ott; L V Coren; E N Chertova; T D Gagliardi; U Schubert
Journal:  Virology       Date:  2000-12-05       Impact factor: 3.616

9.  Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag).

Authors:  L VerPlank; F Bouamr; T J LaGrassa; B Agresta; A Kikonyogo; J Leis; C A Carter
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

10.  A role for ubiquitin ligase recruitment in retrovirus release.

Authors:  B Strack; A Calistri; M A Accola; G Palu; H G Gottlinger
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205
View more
  28 in total

1.  The functionally exchangeable L domains in RSV and HIV-1 Gag direct particle release through pathways linked by Tsg101.

Authors:  Gisselle Medina; Yongjun Zhang; Yi Tang; Eva Gottwein; Marcy L Vana; Fadila Bouamr; Jonathan Leis; Carol A Carter
Journal:  Traffic       Date:  2005-10       Impact factor: 6.215

2.  Release of autoinhibition converts ESCRT-III components into potent inhibitors of HIV-1 budding.

Authors:  Alessia Zamborlini; Yoshiko Usami; Sheli R Radoshitzky; Elena Popova; Giorgio Palu; Heinrich Göttlinger
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-04       Impact factor: 11.205

3.  YRKL sequence of influenza virus M1 functions as the L domain motif and interacts with VPS28 and Cdc42.

Authors:  Eric Ka-Wai Hui; Subrata Barman; Dominic Ho-Ping Tang; Bryan France; Debi P Nayak
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

4.  Differential requirements for Alix and ESCRT-III in cytokinesis and HIV-1 release.

Authors:  Jez G Carlton; Monica Agromayor; Juan Martin-Serrano
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-18       Impact factor: 11.205

5.  Evidence of a role for soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) machinery in HIV-1 assembly and release.

Authors:  Anjali Joshi; Himanshu Garg; Sherimay D Ablan; Eric O Freed
Journal:  J Biol Chem       Date:  2011-06-16       Impact factor: 5.157

Review 6.  Host factors involved in retroviral budding and release.

Authors:  Juan Martin-Serrano; Stuart J D Neil
Journal:  Nat Rev Microbiol       Date:  2011-06-16       Impact factor: 60.633

7.  Heterologous late-domain sequences have various abilities to promote budding of human immunodeficiency virus type 1.

Authors:  David E Ott; Lori V Coren; Tracy D Gagliardi; Kunio Nagashima
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  Context-dependent effects of L domains and ubiquitination on viral budding.

Authors:  Juan Martin-Serrano; David Perez-Caballero; Paul D Bieniasz
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  A catalytically and genetically optimized beta-lactamase-matrix based assay for sensitive, specific, and higher throughput analysis of native henipavirus entry characteristics.

Authors:  Mike C Wolf; Yao Wang; Alexander N Freiberg; Hector C Aguilar; Michael R Holbrook; Benhur Lee
Journal:  Virol J       Date:  2009-07-31       Impact factor: 4.099

10.  The nucleocapsid region of HIV-1 Gag cooperates with the PTAP and LYPXnL late domains to recruit the cellular machinery necessary for viral budding.

Authors:  Vincent Dussupt; Melodi P Javid; Georges Abou-Jaoudé; Joshua A Jadwin; Jason de La Cruz; Kunio Nagashima; Fadila Bouamr
Journal:  PLoS Pathog       Date:  2009-03-13       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.